Jones Financial Companies
KROS icon

Jones Financial Companies’s Keros Therapeutics KROS Stock Holding History

Jones Financial Companies’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.83K Buy
+621
New +$6.92K ﹤0.01% 3949
2026
Q1 		– Sell
-1,396
Closed -$28.4K – 4841
2025
Q4 		$28.4K Buy
+1,396
New +$24.5K ﹤0.01% 2787

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jones Financial Companies's KROS Position: Q2 2026 in Review

Jones Financial Companies opened a new position in Keros Therapeutics (KROS) in Q2 2026: 621 shares worth $6.83K. The stake represents ﹤0.01% of the portfolio and ranks #3949 among its holdings. This is a return to the name: Jones Financial Companies previously reported a position in KROS as recently as Q4 2025.

Jones Financial Companies first reported a position in KROS in Q4 2025 and has held it in 2 quarters since. The position peaked at $28.4K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Jones Financial Companies held 621 shares of Keros Therapeutics worth $6.83K as of Q2 2026.
  • Keros Therapeutics was a new Jones Financial Companies position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3949 holding.
  • Jones Financial Companies first reported a position in Keros Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Jones Financial Companies's Keros Therapeutics position peaked at $28.4K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.